This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.It is currently recommended that 11-12 year-olds and others at increased risk for meningococcal disease be vaccinated with MCV-4 (meningococcal polysaccharide diphtheria toxoid conjugate vaccine). HIV infection can lead to T-cell-dependent B-cell dysfunction, which increases the risk of infection with encapsulated organisms, and perhaps menningococcus. The effectiveness of new conjugate vaccines in HIV-infected youth is not clear, and data on immunologic factors that determine the safety or efficacy of conjugated vaccines in HIV infection are sparse. In this proposal the safety and immunogenicity of conjugated meningococcal vaccine in a broad clinical spectrum of HIV-infected youth will be determined. The main aim is to compare the short-term (28w) and long-term (72w) immunogenicity of MCV4 when given as a single-dose or two-dose regimen stratified on CD4 count at entry. In addition to the evaluation of the safety of the vaccine, the effects of immune status (CD4 count) at the time of vaccination and host genetic determinants of immunity will be evaluated.
Showing the most recent 10 out of 470 publications
